Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its…
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Heart disease in dogs is almost as common as it is in…
Boehringer Ingelheim Commits to Veeva Vault CRM
Top biopharma company selects the next generation of CRM for life sciences as…